See more : Fuji Pharma Co., Ltd. (4554.T) Income Statement Analysis – Financial Results
Complete financial analysis of Sutro Biopharma, Inc. (STRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sutro Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Rockhopper Exploration plc (RCKHF) Income Statement Analysis – Financial Results
- Queen City Investments, Inc. (QUCT) Income Statement Analysis – Financial Results
- Yamaya Corporation (9994.T) Income Statement Analysis – Financial Results
- Luna Innovations Incorporated (LUNA) Income Statement Analysis – Financial Results
- Besunyen Holdings Company Limited (0926.HK) Income Statement Analysis – Financial Results
Sutro Biopharma, Inc. (STRO)
About Sutro Biopharma, Inc.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 153.73M | 67.77M | 61.88M | 42.72M | 42.74M | 38.42M | 51.74M | 59.73M |
| Cost of Revenue | 6.82M | 8.29M | 9.77M | 76.96M | 65.61M | 54.26M | 51.90M | 43.55M |
| Gross Profit | 146.92M | 59.48M | 52.11M | -34.24M | -22.88M | -15.84M | -156.00K | 16.18M |
| Gross Profit Ratio | 95.57% | 87.77% | 84.21% | -80.14% | -53.53% | -41.24% | -0.30% | 27.09% |
| Research & Development | 180.43M | 137.17M | 104.40M | 76.96M | 65.61M | 54.26M | 54.64M | 43.55M |
| General & Administrative | 62.58M | 59.54M | 56.00M | 36.82M | 32.59M | 21.38M | 16.37M | 14.82M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 62.58M | 59.54M | 56.00M | 36.82M | 32.59M | 21.38M | 16.37M | 14.82M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -4.35M | 1.91M | -77.00K | 87.00K |
| Operating Expenses | 243.01M | 196.72M | 160.40M | 113.78M | 98.20M | 75.64M | 71.01M | 58.37M |
| Cost & Expenses | 243.01M | 196.72M | 160.40M | 113.78M | 98.20M | 75.64M | 71.01M | 58.37M |
| Interest Income | 14.51M | 3.46M | 577.00K | 1.51M | 4.07M | 1.62M | 273.00K | 251.00K |
| Interest Expense | 23.75M | 3.35M | 3.14M | 4.08M | 4.35M | 1.62M | 612.00K | 0.00 |
| Depreciation & Amortization | 6.82M | 8.29M | 9.77M | 4.30M | 4.78M | 4.54M | 4.99M | 5.66M |
| EBITDA | -67.92M | -105.07M | -98.52M | -23.75M | -46.62M | -32.82M | -14.09M | 7.36M |
| EBITDA Ratio | -44.18% | -185.16% | -150.46% | -152.74% | -109.08% | -75.89% | -27.22% | 12.33% |
| Operating Income | -89.28M | -128.94M | -98.52M | -71.06M | -55.47M | -37.22M | -19.27M | 1.36M |
| Operating Income Ratio | -58.07% | -190.26% | -159.22% | -166.32% | -129.79% | -96.89% | -37.25% | 2.28% |
| Total Other Income/Expenses | 677.00K | 12.24M | -7.01M | 38.93M | -276.00K | 1.91M | -416.00K | 338.00K |
| Income Before Tax | -88.60M | -116.70M | -105.54M | -32.13M | -55.74M | -35.32M | -19.69M | 1.70M |
| Income Before Tax Ratio | -57.63% | -172.20% | -170.55% | -75.20% | -130.44% | -91.93% | -38.05% | 2.85% |
| Income Tax Expense | 18.19M | 2.50M | 3.14M | 4.08M | 8.68M | 3.53M | 535.00K | 87.00K |
| Net Income | -106.79M | -119.20M | -108.68M | -36.21M | -55.74M | -35.32M | -19.69M | 1.70M |
| Net Income Ratio | -69.47% | -175.89% | -175.62% | -84.75% | -130.44% | -91.93% | -38.05% | 2.85% |
| EPS | -1.78 | -2.35 | -2.36 | -1.11 | -2.43 | -6.13 | -2.81 | 0.24 |
| EPS Diluted | -1.78 | -2.35 | -2.36 | -1.11 | -2.43 | -6.13 | -2.81 | 0.24 |
| Weighted Avg Shares Out | 60.16M | 50.74M | 46.12M | 32.57M | 22.96M | 5.76M | 7.00M | 7.00M |
| Weighted Avg Shares Out (Dil) | 60.16M | 50.74M | 46.12M | 32.57M | 22.96M | 5.76M | 7.00M | 7.00M |
Sutro Biopharma to Participate in Two Virtual Investor Conferences in June
SOUTH SAN FRANCISCO, Calif., June 15, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today...
Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck
Sutro Biopharma Inc (NASDAQ: STRO) has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA Germany (OTC: MKGAF). The payment is related to a patient enrollment achievement in the Phase 1 dose-escalation and expansion study of M1231...
Sutro Biopharma Earns Milestone Payment from Bispecific Antibody-Drug Conjugate Collaboration with Merck KGaA, Darmstadt, Germany
SOUTH SAN FRANCISCO, Calif., June 1, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today...
Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021
SOUTH SAN FRANCISCO, Calif., May 19, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today...
Sutro Biopharma to Participate in Upcoming Virtual Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 14, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today...
Sutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones
SOUTH SAN FRANCISCO, Calif., May 7, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today...
Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck
SOUTH SAN FRANCISCO, Calif., April 15, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today...
Sutro Biopharma to Present at Two Upcoming Investor Conferences
SAN FRANCISCO, April 8, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that...
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
SOUTH SAN FRANCISCO, Calif., March 22, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics,...
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Lags Revenue Estimates
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -164.29% and -32.13%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Source: https://incomestatements.info
Category: Stock Reports